Increased regulatory T‐cell frequencies in patients with advanced melanoma correlate with a generally impaired T‐cell responsiveness and are restored after dendritic cell‐based vaccination
Open Access
- 21 July 2010
- journal article
- research article
- Published by Wiley in Experimental Dermatology
- Vol. 19 (8) , e213-e221
Abstract
Please cite this paper as: Increased regulatory T‐cell frequencies in patients with advanced melanoma correlate with a generally impaired T‐cell responsiveness and are restored after dendritic cell‐based vaccination. Experimental Dermatology 2010; 19: e213–e221.Abstract: Naturally occurring CD4+ CD25+ regulatory T‐cell (Treg) activity is assumed to facilitate tumor development and progression. To elucidate the possible role of Tregs in the course of melanoma progression, we analysed the frequency of Tregs in the peripheral blood of patients at melanoma stages I–IV and in patients at melanoma stage IV that underwent dendritic cell (DC)‐based immunotherapy. Using CD25, Foxp3, CD127 and HLA‐DR as Treg associated markers, we observed increased Treg frequencies in patients at the late melanoma stage (stage IV) when compared to healthy donors. Accumulation of Tregs in patients with progressed melanoma correlated with a general reduction of T‐cell responsiveness to the recall antigens tetanus toxoid and tuberculin‐GT. However, DC‐based immunotherapy not only restored antigen‐specific immunity, but also decreased the frequency of Tregs in peripheral blood of patients with melanoma. These findings indicate that tumor progression in patients with melanoma result in general immunosuppression that is associated with Treg expansion in the periphery and can be overcome by DC‐based vaccination.Keywords
This publication has 48 references indexed in Scilit:
- Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor functionJournal of Translational Medicine, 2009
- Targeted Therapies to Improve Tumor ImmunotherapyClinical Cancer Research, 2008
- Tumor Immunotherapy in MelanomaAmerican Journal of Clinical Dermatology, 2008
- Induction of FOXP3 expression in naive human CD4+FOXP3− T cells by T-cell receptor stimulation is transforming growth factor-β–dependent but does not confer a regulatory phenotypeBlood, 2007
- Immunosuppressive Strategies that are Mediated by Tumor CellsAnnual Review of Immunology, 2007
- Transient expression of FOXP3 in human activated nonregulatory CD4+ T cellsEuropean Journal of Immunology, 2006
- IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivoBlood, 2006
- CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cellsJournal of Experimental Medicine, 2006
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006
- Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humansHuman Immunology, 2005